Weight-loss drug sales explode! Eli Lilly’s Q4 revenue surges 43% year-on-year; net profit rises 50%; 2026 revenue guidance set at $80–83 billion | Financial Report Insights

The 'volume-over-price' strategy delivers: 46% volume growth offsets pricing pressure. A deeper analysis of revenue drivers reveals that Eli Lilly’s growth is entirely volume-driven. In Q4, global product volume surged 46%—a staggering increase that fully offset the negative impact of a 5% decline in realized prices. In the U.S. market, volume soared 50%, while realized prices fell 7%. This primarily reflects rebates and pricing concessions made by Zepbound and Mounjaro to secure broader inclusion in health insurance formularies and expand patient access. Additionally, Lilly announced an agreement with the U.S. government aimed at expanding access to obesity medications for millions of Americans—an initiative that may compress unit pricing but will significantly widen its moat, consolidating its market leadership through economies of scale. Internationally, volume grew 38%, driven mainly by Mounjaro. This signals Lilly’s successful replication of its U.S. success globally—especially as production bottlenecks ease and pent-up global demand is rapidly met. 2026 revenue target of $83 billion dwarfs Novo Nordisk’s outlook. The standout highlight of this earnings report lies in Lilly’s starkly divergent forward outlook compared to Novo Nordisk. Lilly forecasts its 2026 revenue ceiling at $83 billion—implying continued robust growth of over 20% from its already high 2025 base of $65.18 billion. By contrast, Novo Nordisk previously warned investors that intensifying price competition in the weight-loss drug market would cause its full-year sales to decline by 13%. Novo Nordisk CEO Mike Doustdar stated outright that the company faces 'unprecedented pricing pressure' in 2026. Beyond sustained injection-based volume growth, oral weight-loss drugs may be the next game-changer. Lilly is awaiting regulatory approval for its oral weight-loss drug, potentially as early as April this year. The company has already manufactured billions of doses in anticipation of launch. To address pricing demands from the Trump administration and telehealth providers, Lilly announced that—if FDA-approved—the lowest-dose monthly cost of its oral drug will be just $149. This aggressively competitive pricing strategy will strike both high-priced injectables and low-cost generics simultaneously. On profitability, 2026 Non-GAAP EPS guidance stands at $33.50–$35.00. Compared to $24.21 for full-year 2025, this implies roughly 40% EPS growth. Such profit growth outpacing revenue growth stems from rising contributions from high-margin products (gross margin guidance raised to over 83%) and operational leverage. Although Lilly expects continued R&D and marketing investment in 2026, revenue scale effects more than absorb these costs. R&D pipeline and capacity expansion: Building a wider 'moat'. To sustain long-term dominance, Lilly is accelerating its post-tirzepatide strategy, focusing on enhancing dosing convenience and broadening therapeutic indications: Oral weight-loss drug nearing approval: The company has submitted applications for orforglipron—a non-peptide, oral GLP-1 receptor agonist—to the FDA, Japan’s PMDA, and the European Medicines Agency (EMA).

Forward-looking analysis of 2027 National Natural Science Foundation (NSFC) research hotspots

Top 10 Biomedical Research Hotspots in 2026 1. AI-powered drug discovery becomes R&D 'infrastructure': Tech giants including Google and Anthropic view AI-driven drug development as a core growth engine; NVIDIA and Eli Lilly jointly built a supercomputer dedicated to molecular simulation—AI has evolved from an auxiliary tool into the primary channel for drug discovery. 2. Gene editing advances toward in vivo application and universality: An中科院 (CAS) team achieved direct in vivo reprogramming of anti-cancer T cells using a 'dual-particle' delivery system; in vivo editing pipelines (e.g., CTX460) have entered Phase I clinical trials; research focus is shifting from single-disease customization to universal technology frameworks. 3. Brain-computer interfaces (BCIs) enter the global top tier: China has achieved full-stack independent innovation in BCIs, entering the world’s elite tier; CNS-related sub-diseases have simultaneously become focal points of global M&A 'FOMO' (fear of missing out). 4. Weight-loss drugs enter the 'oral era' for GLP-1-based therapies: Wegovy oral tablets launched in the U.S. in January; generated $855 million in sales in H1 and surpassed 5 million prescriptions cumulatively; Eli Lilly’s oral small-molecule orforglipron received FDA approval; the EU approved its first oral GLP-1 weight-loss drug. 5. Antibody-drug conjugates (ADCs) undergo continuous iteration: Bispecific ADCs and dual-payload ADCs are now mainstream; at AACR 2026, Chinese biopharma companies showcased 92 ADC candidates—accounting for nearly 40% of all innovative drugs presented; the world’s first bispecific ADC (BL-B01D1) gained regulatory approval. 6. Bispecific/multispecific antibodies and T-cell engagers (TCEs) dominate BD deals: Yivocixumab outperformed Keytruda head-to-head in first-line PD-L1+ NSCLC, achieving a median overall survival (OS) of 30.8 months; bispecific/multispecific antibodies and TCEs are now top priorities for outbound licensing. 7. Small nucleic acid therapeutics accelerate breakthroughs: SOD1 siRNA (RAG-17) for ALS demonstrated promising Phase I results published in Nature Medicine; RNA exon-skipping therapy for Duchenne muscular dystrophy (DMD) appeared in Cell; extrahepatic targeting—particularly cardiac targeting—is emerging as a key delivery focus. 8. Cell therapies tackle solid tumors: Domestic CAR-T therapy (Shuruiji Olunsel) received approval, filling a critical gap in later-line treatment for advanced gastric cancer; CAR-T and iPSC-based multi-track pipelines are advancing in parallel. 9. Radiopharmaceuticals achieve '0-to-1' breakthrough: China’s first independently developed Class 1 innovative radiopharmaceutical—Technetium [⁹⁹ᵐTc] Pexidartinib Peptide—was approved in April, becoming the world’s first integrin αvβ3-targeted radiotracer for imaging; radiopharmaceuticals have emerged as a premium M&A segment globally. 10. Chinese innovative drugs expand overseas and boost BD transactions: In H1 2026, global R&D licensing deal value totaled $166.7 billion; Chinese assets accounted for 42% of large licensing deals (upfront ≥ $50 million) and 68% of total upfront payments; transaction models have evolved from single-product license-outs to multi-program collaborations, co-development, and NewCo formations. Policy context: In September, ten government departments jointly issued a notice prioritizing oncology, autoimmune diseases, metabolic disorders, cardiovascular conditions, and neurological diseases—and explicitly endorsing AI, quantum computing, and supercomputing to empower R&D and explore novel bio-manufacturing paradigms. Biopharmaceuticals have also been designated a strategic emerging pillar industry under China’s 15th Five-Year Plan ('Fifteenth Five-Year Plan').

Eli Lilly's Weight-Loss Pill Wins EU Drug Regulator's Backing

19 hours ago

The EMA recommended approval of Eli Lilly's oral weight-loss drug Foundayo, becoming the second such authorization after Novo Nordisk. Final EC approval is pending before launch in a market projected to exceed $100 billion by 2030.

reuters

2026-01-13

Jan. 13 Business Watch: Plants Close in Brazil and the UK; Lilly to Pay $1.2 Billion for Ventyx

2026-04-17

Lilly's obesity pill Foundayo gets 1,390 prescriptions in debut week

2026-04-19

Eli Lilly in advanced talks to acquire Kelonia Therapeutics for over $2 billion, WSJ says

2026-04-24

Eli Lilly's Obesity Pill Records Modest Second Week as Battle with Novo Nordisk Intensifies

2026-04-30

S&P 500, Nasdaq On Course for Best Month Since 2020 Despite Middle East Risks